Ozempic vs. Wegovy

Are Ozempic and Wegovy the same drug?

Yes — both are semaglutide, the same active ingredient from the same manufacturer. The differences are what each is approved for, the doses each comes in, and how they're covered by insurance. Ozempic is approved for type 2 diabetes; Wegovy is approved for weight management [1], [2].

Because the molecule is identical, they share the same mechanism, the same side effects, and the same boxed warning — they are not chemically different medications.

What is Ozempic?

Ozempic is a once-weekly injectable GLP-1 receptor agonist FDA-approved to improve blood sugar in adults with type 2 diabetes, and to reduce the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) in adults with type 2 diabetes and established heart disease [1]. It is dosed 0.25 mg to a maximum of 2 mg once weekly.

Because semaglutide also reduces appetite, Ozempic is widely prescribed off-label for weight loss — but it has not been FDA-approved for that use, and it is not available at the 2.4 mg weight-management dose [1].

As of January 2025, Ozempic is also FDA-approved to reduce the risk of worsening kidney disease and cardiovascular death in adults who have both type 2 diabetes and chronic kidney disease [1].

What is Wegovy?

Wegovy is the same molecule — semaglutide — FDA-approved specifically for chronic weight management in adults and adolescents (12+) with obesity, or overweight plus a weight-related condition such as high blood pressure or high cholesterol [2].

In 2024 it also gained approval to reduce cardiovascular risk in adults with established heart disease and obesity or overweight, based on the SELECT trial, which found a 20% reduction in major cardiovascular events [2], [4]. Wegovy titrates over ~16+ weeks to a maintenance dose of 2.4 mg once weekly [2].

How they work (mechanism)

Both drugs mimic GLP-1, a natural gut hormone released after eating. They slow how fast the stomach empties, prompt insulin release when blood sugar is high, and quiet hunger and "food noise" in the brain [1], [2].

That single mechanism is why semaglutide both lowers blood sugar (the diabetes use) and reduces body weight (the obesity use) — and why the side effects are the same. The practical difference between Ozempic and Wegovy is not how they work, but the dose ceiling and the approved indication.

Effectiveness: which works better for weight loss?

For weight loss, Wegovy has the stronger evidence — because it's the version tested and dosed for it. In STEP 1, adults without diabetes lost a mean 14.9% of body weight at 68 weeks on Wegovy (2.4 mg), versus 2.4% on placebo, and about a third lost ≥20% of their body weight [3].

Ozempic, studied mainly in type 2 diabetes at up to 1–2 mg, produces more modest weight loss (roughly 6% at 1 mg in diabetes trials) and is not optimized to the 2.4 mg dose [1]. Pharmacologically, an identical milligram dose of semaglutide produces an identical effect — but since Ozempic stops at 2 mg, it cannot reach Wegovy's full weight-management dose.

What to expect: timeline

Semaglutide works gradually, not overnight. The dose starts low and steps up about every 4 weeks, so appetite usually eases within the first few weeks while most of the weight comes off over the following months. In STEP 1, average weight loss was still building at 68 weeks, when the −14.9% figure was measured [3]. It then tends to slow and plateau.

Because it treats a chronic condition, weight typically returns if you stop, so it is intended as long-term, supervised therapy rather than a short course [1], [2].

Dosing & administration

Both are once-weekly subcutaneous injections in prefilled pens, started low and titrated up roughly every 4 weeks to limit nausea [1], [2].

Ozempic dosing

0.25 mg (4 weeks, start) → 0.5 mg → 1 mg → 2 mg maximum, once weekly [1].

Wegovy dosing

0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg maintenance, once weekly [2].

A given dose is interchangeable in effect (1 mg of Wegovy ≈ 1 mg of Ozempic), but only Wegovy offers the 1.7 mg and 2.4 mg weight-management steps.

Side effects & safety

Side effects are the same for both because the drug is the same — predominantly gastrointestinal, usually mild-to-moderate, and worst in the weeks after starting or moving up a dose [1], [2].

Common side effects (both)

Nausea, diarrhea, vomiting, constipation, abdominal pain. Most ease as the body adjusts [1], [2].

Serious risks & boxed warning

Both carry a boxed warning for thyroid C-cell tumors seen in rodents; both are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 [1], [2]. Less common but serious risks include pancreatitis, gallbladder disease, and — when combined with insulin or sulfonylureas — low blood sugar [1], [2].

Who should not take it (and key cautions)

Semaglutide is not for everyone. It is contraindicated if you or a close family member has had medullary thyroid carcinoma (MTC) or MEN 2, or if you've had a serious allergic reaction to it [1], [2].

Use caution — or avoid — with a history of pancreatitis, gallbladder disease, severe gastrointestinal disease, or diabetic retinopathy, which the Ozempic label flags for monitoring [1]. Because the drug stays in the body for weeks, it should be stopped at least 2 months before a planned pregnancy [2].

Share your full medical history with your clinician before starting.

Cost & insurance coverage

Without insurance, both run roughly $1,000–$1,350 per month at list price (Wegovy is typically higher) [1], [2]. Coverage is the real differentiator: insurers more often cover Ozempic for diagnosed type 2 diabetes, while weight-loss coverage for Wegovy is inconsistent — which is a major reason some people are prescribed Ozempic off-label.

Manufacturer savings programs (NovoCare), and a supervised medical-weight-loss program like JumpstartMD's, can change the real out-of-pocket figure substantially.

A note on compounded versions: compounded GLP-1 medications can be a lower-cost route, and the rules around them shifted as the recent shortages resolved [5]. Quality and physician oversight vary by source, so a compounded option should come from a licensed, supervised medical program using a reputable compounding pharmacy — not an anonymous online seller.

JumpstartMD prescribes and supervises these medications, including compounded options where appropriate.

Can you switch from Ozempic to Wegovy?

Yes, and it's common — usually to reach the higher 2.4 mg weight-management dose. Because it's the same drug, a clinician can often transition you at a comparable dose and continue titrating. Switching should be supervised so the dose ladder and side-effect management are handled correctly.

Which is right for you?

• You have type 2 diabetes → Ozempic is the on-label, usually better-covered choice (and still supports weight loss).
• Your primary goal is weight loss → Wegovy is the FDA-approved, full-dose option with the strongest weight-loss evidence.
• You have heart disease plus obesity → Wegovy is now approved to lower cardiovascular risk in that group [4].

The right answer depends on your diagnosis, insurance, and history — which is exactly what a supervised consultation sorts out. JumpstartMD physicians prescribe and manage both, including dose titration and side-effect management.